SMARCC1 Expression is Positively Correlated with Pathological Grade and Good Prognosis in Renal Cell Carcinoma

Overview

Journal Transl Androl Urol

Date 2021 Feb 3

PMID 33532313

Citations 2

Authors

Gangmin Wang

Qi Lv

Chunhui Ma

Yinan Zhang

Haoming Li

Qiang Ding

Affiliations

Soon will be listed here.

Abstract

Background: Renal cell carcinoma (RCC), which is derived from the renal tubular epithelium, is now the most common urological cancer. Of the four RCC subtypes, clear cell RCC (ccRCC) is the most common subtype and accounts for 75-80% of all RCC cases. SMARCC1, also known as BAF155, together with SMARCA4, SMARCA2, and SMARCB1, comprises the SWI/SNF protein family. It has been reported that the expression of SMARCC1 was correlated with some human cancers including prostate cancer, colon cancer, and pancreatic cancer. However, the mechanisms and regulatory roles of SMARCC1 in ccRCC are not well defined.

Methods: Our current study primarily investigated the expression of SMARCC1 and its clinical importance in two common histological types of ccRCC using microarrays (HKidE180Su02, MecDNA-HKidE030CS01).

Results: The results showed that the expression of SMARCC1 in ccRCC tissues was significantly decreased compared with that in corresponding para-tumor tissue (4.370±2.036 6.167±1.162, P=0.001). SMARCC1 expression was positively correlated with pathological grade (r=0.224, P=0.011). Moreover, ccRCC patients with high SMARCC1 expression had a better prognosis than those with low SMARCC1 expression (40.0% 95.2%, P=0.000) in the following sub-groups: pathological grade (III and IV), male sex (73.5% 95.3%, P=0.004), and tumor size >5 cm (62.5% 89.5%, P=0.044).

Conclusions: A further study is necessary to explain the mechanism of the occurrence and progression of ccRCC.

Citing Articles

High expression of SMARCC1 predicts poor prognosis in gastric cancer patients.

Liu S, Cao X, Wu S Am J Cancer Res. 2022; 12(9):4428-4438.

PMID: 36225646 PMC: 9548000.

Suppresses Tumor Progression by Inhibiting the PI3K/AKT Signaling Pathway in Prostate Cancer.

Xiao Z, Lv D, Yu Y, Wang C, Xie T, Wang T Front Cell Dev Biol. 2021; 9:678967.

PMID: 34249931 PMC: 8267926. DOI: 10.3389/fcell.2021.678967.

References

Heeboll S, Borre M, Ottosen P, Andersen C, Mansilla F, Dyrskjot L . SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. Histol Histopathol. 2008; 23(9):1069-76. DOI: 10.14670/HH-23.1069. View

Wang L, Zhao Z, Meyer M, Saha S, Yu M, Guo A . CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis. Cancer Cell. 2016; 30(1):179-180. DOI: 10.1016/j.ccell.2016.06.013. View

Hansen R, Heeboll S, Ottosen P, Dyrskjot L, Borre M . Smarcc1 expression: a significant predictor of disease-specific survival in patients with clinically localized prostate cancer treated with no intention to cure. Scand J Urol Nephrol. 2010; 45(2):91-6. DOI: 10.3109/00365599.2010.530295. View

Andersen C, Christensen L, Thorsen K, Schepeler T, Sorensen F, Verspaget H . Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. Br J Cancer. 2009; 100(3):511-23. PMC: 2658541. DOI: 10.1038/sj.bjc.6604884. View

Baldewijns M, van Vlodrop I, Schouten L, Soetekouw P, de Bruine A, van Engeland M . Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta. 2008; 1785(2):133-55. DOI: 10.1016/j.bbcan.2007.12.002. View

Rabjerg M, Bjerregaard H, Halekoh U, Jensen B, Walter S, Marcussen N . Molecular characterization of clear cell renal cell carcinoma identifies CSNK2A1, SPP1 and DEFB1 as promising novel prognostic markers. APMIS. 2016; 124(5):372-83. DOI: 10.1111/apm.12519. View

Schaniel C, Ang Y, Ratnakumar K, Cormier C, James T, Bernstein E . Smarcc1/Baf155 couples self-renewal gene repression with changes in chromatin structure in mouse embryonic stem cells. Stem Cells. 2009; 27(12):2979-91. PMC: 5978760. DOI: 10.1002/stem.223. View

Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

DelBove J, Rosson G, Strobeck M, Chen J, Archer T, Wang W . Identification of a core member of the SWI/SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene. Epigenetics. 2011; 6(12):1444-53. PMC: 3256333. DOI: 10.4161/epi.6.12.18492. View

10.

Agaimy A, Amin M, Gill A, Popp B, Reis A, Berney D . SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients. Hum Pathol. 2018; 77:139-146. DOI: 10.1016/j.humpath.2018.04.004. View

11.

Vera-Badillo F, Templeton A, Duran I, Ocana A, de Gouveia P, Aneja P . Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol. 2014; 67(4):740-9. DOI: 10.1016/j.eururo.2014.05.010. View

12.

Gupta K, Miller J, Li J, Russell M, Charbonneau C . Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008; 34(3):193-205. DOI: 10.1016/j.ctrv.2007.12.001. View

13.

Ke S, Qiu H, Chen J, Shi W, Chen Y . MicroRNA-202-5p functions as a tumor suppressor in colorectal carcinoma by directly targeting SMARCC1. Gene. 2018; 676:329-335. DOI: 10.1016/j.gene.2018.08.064. View

14.

Iwagami Y, Eguchi H, Nagano H, Akita H, Hama N, Wada H . miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer. 2013; 109(2):502-11. PMC: 3721395. DOI: 10.1038/bjc.2013.320. View

15.

Wang Y, Wan F, Chang K, Lu X, Dai B, Ye D . NUDT expression is predictive of prognosis in patients with clear cell renal cell carcinoma. Oncol Lett. 2017; 14(5):6121-6128. PMC: 5661574. DOI: 10.3892/ol.2017.6997. View